Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

On the heels of two FDA approvals in lung cancer treatments, what innovations are next? As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

ZL-1310, targeting DLL3, shows early antitumor activity in extensive-stage SCLC, with 74% of patients experiencing tumor shrinkage or disappearance. The FDA's fast track designation for ZL-1310 ...

Please provide your email address to receive an email when new articles are posted on . Patients with small cell lung cancer who had higher levels of detectable ctDNA mutations at diagnosis had worse ...

Tarlatamab is a bispecific T-cell engager (BiTE) that binds to delta-like ligand-3 (DLL3) on small cell lung cancer (SCLC) cells and cluster of differentiation-3 on T cells, thereby delivering ...